27284491|t|Mutation profiles of synchronous colorectal cancers from a patient with Lynch syndrome suggest distinct oncogenic pathways
27284491|a|Patients with Lynch syndrome often present with multiple synchronous or metachronous colorectal cancers (CRCs). The presence of multiple CRCs with distinct genetic profiles and driver mutations could complicate treatment as each cancer may respond differently to therapy. Studies of sporadic CRCs suggested that synchronous tumors have distinct etiologies, but could not rule out differences in genetic background. The presence of multiple cancers in a patient with a predisposing mutation provides an opportunity to profile synchronous cancers in the same genetic background. Here, we describe the case of a patient with Lynch syndrome that presented with six synchronous CRCs. Microsatellite instability (MSI) and genomic profiling indicated that each lesion had a unique pattern of instability and a distinct profile of affected genes. These findings support the idea that in Lynch syndrome, synchronous CRCs can develop in parallel with distinct mutation profiles and that these differences may inform treatment decisions.
27284491	0	8	Mutation	T045	C0026882
27284491	9	17	profiles	T169	C2003903
27284491	21	32	synchronous	T191	C0027663
27284491	33	51	colorectal cancers	T191	C1527249
27284491	59	66	patient	T101	C0030705
27284491	72	86	Lynch syndrome	T191	C1333990
27284491	104	113	oncogenic	T191	C0596263
27284491	114	122	pathways	T077	C1705987
27284491	123	131	Patients	T101	C0030705
27284491	137	151	Lynch syndrome	T191	C1333990
27284491	171	191	multiple synchronous	T191	C0027663
27284491	195	207	metachronous	T191	C1334703
27284491	208	226	colorectal cancers	T191	C1527249
27284491	228	232	CRCs	T191	C1527249
27284491	251	259	multiple	T081	C0439064
27284491	260	264	CRCs	T191	C1527249
27284491	279	295	genetic profiles	T059	C2986505
27284491	307	316	mutations	T045	C0026882
27284491	323	333	complicate	T169	C0231242
27284491	334	343	treatment	T169	C0039798
27284491	352	358	cancer	T191	C0006826
27284491	363	370	respond	T032	C0871261
27284491	371	382	differently	T080	C1705242
27284491	386	393	therapy	T061	C0087111
27284491	406	414	sporadic	T033	C1853237
27284491	415	419	CRCs	T191	C1527249
27284491	435	453	synchronous tumors	T191	C0027663
27284491	459	478	distinct etiologies	T169	C0015127
27284491	518	536	genetic background	T032	C4042916
27284491	554	570	multiple cancers	T191	C0346429
27284491	576	583	patient	T101	C0030705
27284491	591	603	predisposing	T169	C0231203
27284491	604	612	mutation	T045	C0026882
27284491	625	636	opportunity	T062	C0683937
27284491	640	647	profile	T169	C2003903
27284491	648	667	synchronous cancers	T191	C0027663
27284491	680	698	genetic background	T032	C4042916
27284491	732	739	patient	T101	C0030705
27284491	745	759	Lynch syndrome	T191	C1333990
27284491	784	795	synchronous	T191	C0027663
27284491	796	800	CRCs	T191	C1527249
27284491	802	828	Microsatellite instability	T046	C0920269
27284491	830	833	MSI	T046	C0920269
27284491	839	856	genomic profiling	T059	C2986505
27284491	877	883	lesion	T033	C0221198
27284491	890	896	unique	T080	C1710548
27284491	897	904	pattern	T082	C0449774
27284491	908	919	instability	T033	C1444783
27284491	926	942	distinct profile	T169	C2003903
27284491	946	960	affected genes	T028	C0017337
27284491	968	976	findings	T169	C2607943
27284491	1002	1016	Lynch syndrome	T191	C1333990
27284491	1018	1034	synchronous CRCs	T191	C0027663
27284491	1073	1081	mutation	T045	C0026882
27284491	1082	1090	profiles	T169	C2003903
27284491	1129	1148	treatment decisions	T033	C4061230